Drug Profile
Research programme: multiple sclerosis therapies - Merck Serono
Latest Information Update: 25 Mar 2009
Price :
$50
*
At a glance
- Originator Merck Serono
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 25 Mar 2009 Discontinued - Preclinical for Multiple sclerosis in France (unspecified route)
- 08 Jan 2007 Serono is now called Merck Serono
- 05 Jan 2007 Serono has been acquired by Merck KGaA